Mesh exposure after ventral hernia repair with onlay biosynthetic mesh: a retrospective review of associated risk factors and management strategies
Hernia · 2024
DOI: 10.1007/s10029-024-03108-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hernia, 2024. Verfasst von Chris Amro und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Plastic Surgery, Department of Surgery, University of Pennsylvania Health System, PCAM South Pavilion 14th Floor, 3400 Civic Center Boule…. Hauptthemen laut MEDLINE: Surgical Mesh, Hernia, Ventral, Herniorrhaphy. Die Arbeit nennt 62 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Although intraperitoneal and retromuscular mesh placement in ventral hernia repair (VHR) are associated with lower recurrence rates, the onlay plane remains a well-established option for certain clinical scenarios. A knowledge gap remains regarding resorbable biosynthetic onlay mesh and mesh exposure. We aim to determine exposure rate, risk factors, and treatment options. STUDY DESIGN: A single-center, two-surgeon retrospective review was performed examining patients who underwent VHR with onlay, Poly-4-hydroxybutyrate (P4HB) mesh from 2015 to 2021. Demographics, operative characteristics, outcomes, and mesh exposure management were analyzed. RESULTS: Of 346 patients, 15 (4.3%) experienced mesh exposure. The mean age was 53 years and BMI of 33.6 kg/m2. Patients were majority ASA class 3 (65%), female (64.2%), and averaged a defect size of 307.9 ± 235.2 cm2. Independent risk factors included diabetes (AOR = 4.3,CI 1.5-12.5;p < 0.005) and COPD (AOR = 5.2,CI 1.3-21.8;p = 0.02). Mesh exposures were identified as outpatient (20%) or intraoperative (80%). All underwent operative debridement, in which nine were managed with skin reclosure, two with partial closure, and four healed by secondary intention. Five patients required excision of unincorporated mesh. Four patients required further debridement from chronic surgical site occurrences; however, all mesh exposure patents healed after a mean of 260.8 ± 313.2 days and retained original mesh. The recurrence rate was 6.7% for mesh exposure patients. CONCLUSION: When faced with mesh exposure, resorbable biosynthetic mesh placed in onlay fashion was retained in all patients. Patients with a history of diabetes or COPD have increased risk of mesh exposure and should be counseled.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Plastic Surgery, Department of Surgery, University of Pennsylvania Health System, PCAM South Pavilion 14th Floor, 3400 Civic Center Boulevard, Philadelphia, PA, 19104, USA. chris.amro542@gmail.com.
- Hansjörg Wyss Department of Plastic Surgery, New York University Langone Health, New York, N.Y, USA. chris.amro542@gmail.com.
- Division of Plastic Surgery, Department of Surgery, University of Pennsylvania Health System, PCAM South Pavilion 14th Floor, 3400 Civic Center Boulevard, Philadelphia, PA, 19104, USA.
ORCID-Profile: Chris Amro
Zitieren
APA
Amro, C., Ryan, I., Lemdani, M. S., Bascone, C. M., McAuliffe, P. B., Desai, A. A., McGraw, J. R., Broach, R. B., Kovach, S. J., & Fischer, J. P. (2024). Mesh exposure after ventral hernia repair with onlay biosynthetic mesh: a retrospective review of associated risk factors and management strategies. Hernia. https://doi.org/10.1007/s10029-024-03108-7
Vancouver
Amro C, Ryan I, Lemdani MS, Bascone CM, McAuliffe PB, Desai AA, et al. Mesh exposure after ventral hernia repair with onlay biosynthetic mesh: a retrospective review of associated risk factors and management strategies. Hernia. 2024. doi:10.1007/s10029-024-03108-7
BibTeX
@article{Amro2024,
author = {Amro, Chris and Ryan, Isabel and Lemdani, Mehdi S and Bascone, Corey M and McAuliffe, Phoebe B and Desai, Abhishek A and McGraw, J Reed and Broach, Robyn B and Kovach, Stephen J and Fischer, John P},
title = {Mesh exposure after ventral hernia repair with onlay biosynthetic mesh: a retrospective review of associated risk factors and management strategies},
journal = {Hernia},
year = {2024},
doi = {10.1007/s10029-024-03108-7}
}
EUVIMED